Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Shanghai MicroPort MedBot (Group) Co., Ltd. Class H ( (HK:2252) ).
Shanghai MicroPort MedBot reported a sharp ramp-up in commercial performance for 2025, with revenue surging 114.2% year-on-year to RMB551.1 million, driven primarily by breakthrough progress in the rollout of its Toumai laparoscopic surgical robot. Overseas expansion of Toumai was a key growth driver, with more than 100 new international orders signed and foreign sales revenue growing to more than five times the prior year, significantly outpacing the industry.
Despite remaining loss-making, the group materially narrowed its net loss to RMB254.1 million from RMB647.1 million, helped by higher gross profit from cost reductions and efficiency gains, lower operating expenses, and reduced impairment charges on overseas investments. Management’s focus on revenue growth, strategic prioritisation and cost discipline also improved cash dynamics, with free cash flow turning positive in the second half and the full-year cash outflow shrinking to RMB63 million from RMB388 million, signalling progress toward financial sustainability.
The most recent analyst rating on (HK:2252) stock is a Buy with a HK$33.00 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.
More about Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai MicroPort MedBot (Group) Co., Ltd. is a mainland China-based medical technology company focused on robotic-assisted surgery. Its core product is the Toumai laparoscopic surgical robot, which the group is actively commercialising in both domestic and overseas markets, positioning itself in the high-growth surgical robotics segment.
Average Trading Volume: 8,253,905
Technical Sentiment Signal: Buy
Current Market Cap: HK$24.94B
See more data about 2252 stock on TipRanks’ Stock Analysis page.